Description
Retatrutide is a next-generation triple receptor agonist peptide supplied in multiple concentration options (12mg, 15mg, and 30mg) for laboratory and scientific research use. It is widely studied in experimental settings focusing on metabolic regulation, energy balance signaling, and multi-receptor pathway interactions.
Manufactured under strict quality control standards, Retatrutide is provided in a high-purity lyophilized form to ensure stability, consistency, and reproducibility across advanced research applications.
Available Strengths
- Retatrutide 12mg
- Retatrutide 15mg
- Retatrutide 30mg
Each vial is formulated for precise laboratory measurement and controlled research protocols.
Key Features
- High-Purity Research Grade Peptide
- Triple Receptor Agonist (GIP / GLP-1 / Glucagon research model)
- Multiple Strength Options for flexible research design
- Sterile Lyophilized Powder Form for long-term stability
- Batch-Tested Quality Assurance with COA availability
Specifications
- Product Name: Retatrutide
- Strength Options: 12mg / 15mg / 30mg per vial
- Form: Freeze-dried (lyophilized) powder
- Type: Synthetic multi-receptor peptide analogue
- Storage: Store in a cool, dry place. Refrigeration recommended after reconstitution in research environments
- Purity: ≥ 99% (subject to batch COA verification)
- Usage: Laboratory and scientific research only
Packaging
Each vial is sealed in sterile, tamper-resistant packaging to ensure maximum stability and integrity. Every unit includes a unique batch identifier for traceability and quality control.
Quality Control
Each batch may undergo strict analytical verification, including:
- High-Performance Liquid Chromatography (HPLC)
- Mass Spectrometry (if applicable)
- Identity and purity confirmation
- Certificate of Analysis (COA) per batch
Important Notice
This product is intended strictly for research and laboratory purposes only. It is not intended for human consumption, medical use, diagnosis, or therapeutic application.




Reviews
There are no reviews yet.